Celcuity Inc. (NASDAQ:CELC) is highlighted as one of the 12 Best Performing Healthcare Stocks to Buy Right Now. The company focuses on developing targeted oncology therapies for solid tumors like advanced breast cancer. Its lead drug candidate, gedatolisib, targets key tumor growth pathways to improve outcomes for patients.

In August 2025, the U.S. FDA accepted Celcuity Inc.’s New Drug Application (NDA) for gedatolisib under the RTOR program. This allows for a faster regulatory process after positive Phase 3 trial results showing reduced disease progression risk and improved survival rates. The therapy has Breakthrough Therapy and Fast Track designations.

Celcuity Inc. recently expanded its senior secured credit facility to $500 million to support late-stage development and commercialization efforts. This move strengthens the company’s financial position, ensuring resources are in place for potential FDA approval and market launch of gedatolisib.

While Celcuity Inc. shows promise as an investment, some AI stocks may offer greater upside potential with lower downside risk. Investors seeking an undervalued AI stock benefitting from tariffs and onshoring trends can explore a free report on the best short-term AI stock for potential opportunities.

Read more at Yahoo Finance: Celcuity Inc. (CELC)’s FDA NDA for Gedatolisib Accepted Under RTOR, Accelerating Review